Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Achieve Life SciencesSTU:SP4P +6.80%38 ROC (Joel Greenblatt) % is -70,581.44% as of Mar. 2026. GuruFocus rates STU:SP4P with a GF Score™ of 38/100. The stock has 4 warning signs investors should review. Among 1,323 Biotechnology companies, Achieve Life Sciences ranks worse than 97.66% on this metric.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Achieve Life Sciences's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -70,581.44%.
The historical rank and industry rank for Achieve Life Sciences's ROC (Joel Greenblatt) % or its related term are showing as below:
STU:SP4P'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -65320.97 Med: -27896.46 Max: -284.72
Current: -65320.97
During the past 13 years, Achieve Life Sciences's highest ROC (Joel Greenblatt) % was -284.72%. The lowest was -65320.97%. And the median was -27896.46%.
STU:SP4P's ROC (Joel Greenblatt) % is ranked worse than 97.66% of 1323
companies
in the Biotechnology industry
Industry Median: -297.52
vs STU:SP4P: -65320.97
Achieve Life Sciences's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was -41.50% per year.
Achieve Life Sciences (STU:SP4P) ROC (Joel Greenblatt) % Explanation
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
Achieve Life Sciences ROC (Joel Greenblatt) % Related Terms
Achieve Life Sciences ROC (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Achieve Life Sciences's ROC (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Achieve Life Sciences ROC (Joel Greenblatt) % Chart
STU:SP4P vs STTK, CRMD, EIKN: ROC (Joel Greenblatt) % Comparison
For the Biotechnology subindustry, Achieve Life Sciences's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Achieve Life Sciences ROC (Joel Greenblatt) % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Achieve Life Sciences's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Achieve Life Sciences's ROC (Joel Greenblatt) % falls into.
Achieve Life Sciences ROC (Joel Greenblatt) % Calculation
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of -70,581.44% mean?
Achieve Life Sciences (STU:SP4P) has a ROC (Joel Greenblatt) % of -70,581.44% as of Mar. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Achieve Life Sciences and its competitors. According to the industry distribution chart, Achieve Life Sciences ranks #1292 out of 1323 companies in the Biotechnology industry, placing it in the top 97.7%.
Is Achieve Life Sciences' ROC (Joel Greenblatt) % too high?
Achieve Life Sciences' current ROC (Joel Greenblatt) % is -70,581.44%. Based on the distribution chart, Achieve Life Sciences ranks #1292 out of 1323 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Achieve Life Sciences has a GF Score™ of 38/100, reflecting its overall financial health beyond just this single metric.
How does Achieve Life Sciences' ROC (Joel Greenblatt) % compare to STTK and CRMD?
According to the Biotechnology industry distribution chart, Achieve Life Sciences ranks #1292 out of 1323 companies for ROC (Joel Greenblatt) %. This places Achieve Life Sciences in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Biotechnology company?
A good ROC (Joel Greenblatt) % depends on the Biotechnology industry context. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Achieve Life Sciences and its competitors. Achieve Life Sciences's current ROC (Joel Greenblatt) % is -70,581.44%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Achieve Life Sciences stock overvalued right now?
Achieve Life Sciences (STU:SP4P) has a current ROC (Joel Greenblatt) % of -70,581.44%. The current ROC (Joel Greenblatt) % is -70,581.44%. Achieve Life Sciences' overall GF Score™ is 38/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Achieve Life Sciences (STU:SP4P), the current ROC (Joel Greenblatt) % is -70,581.44% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Achieve Life Sciences Inc is a late-stage clinical specialty pharmaceutical company with the sole mission to address the nicotine dependence epidemic through the development and commercialization of cytisinicline. Cytisinicline, is a naturally occurring alkaloid. Additionally, The company has completed a Phase 2 study with cytisinicline in vaping cessation and conducted a successful end-of-Phase 2 meeting with the FDA for a future vaping indication. It operates in one operating segment, development and commercialization of cytisinicline for nicotine dependence, with operations located in Canada, the United States and the U.K.
38GF Score
Get the complete analysis for STU:SP4P
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:SP4P has been successfully added to your 
